Hypoxia
Drug research and approvals for hypoxia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 19, 2026, 233 studies of hypoxia are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 233
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Effects of Hypoxia or Caffeine on 4km Time-trial Morning Cycling.NCT07936006 · Phase 4 · Liverpool John Moores University · starts Nov 15, 2026
- Minimal Sedation Versus Standard Continuous Sedation After Out-of-Hospital Cardiac ArrestNCT07895771 · Not applicable · University Medical Centre Ljubljana · starts Sep 22, 2026
- Effects of Tart Cherry and Aronia Extract Supplementation on Selected Physiological Parameters in Endurance-Trained MenNCT07885098 · Not applicable · Wroclaw Medical University · starts Nov 9, 2026
- Newborn Brain Assessment - CergenX WaveNCT07857070 · Not reported · CergenX Limited · starts Oct 22, 2026
- BMI-Adjusted PEEP During One-Lung Ventilation in Thoracic SurgeryNCT07851740 · Not applicable · Jesús Manuel Nieves Alonso · starts Oct 7, 2026
- Group-based Emotional Awareness and Expression Therapy to Support Recovery After Acquired Brain Injury: A Clinical…NCT07852936 · Not applicable · Uppsala University · starts Sep 15, 2026
- PAH-SDB: Sleep-Disordered Breathing and Outcomes in Pulmonary Arterial HypertensionNCT07852403 · Not reported · Chinese Pulmonary Vascular Disease Research Group · starts Oct 1, 2026
- Developing New Ways to Detect Respiratory Impairment Early in ALSNCT07844590 · Not reported · Thomas Jefferson University · starts Sep 1, 2026
- Cerebral Oximetry in Management of Post Cardiac ArrestNCT07829887 · Not applicable · University of Calgary · starts Oct 10, 2025
Phase 3 2
- CaffeineAdenosine receptor antagonist
- Nitric oxideSoluble guanylate cyclase activator
Phase 2 1
- Dornase alfaDNA hydrolytic enzyme
Phase 1 or earlier 7
- Ascorbic acidSupplement
- KetorolacCyclooxygenase inhibitor
- TilarginineNitric oxide synthase inhibitor
- Transcrocetin
- AES-103
- PropranololBeta-1 adrenergic receptor antagonist
- OxygenEssential for cellular homeostasis
How its trials ended
1,141 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 157 whose ending is known, 36% met their primary endpoint, 9% missed it and 55% stopped early.
- Completed, result not reported54748%
- Ongoing24521%
- Status unknown19217%
- Met its primary endpoint565%
- Stopped: other or unclear525%
- Stopped: enrollment or feasibility182%
- Missed its primary endpoint141%
- Stopped: lack of efficacy81%
- Stopped: sponsor or business decision61%
- Stopped: funding3<1%
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Mar 6, 1985 | Superoxide dismutase (human)For protection of donor organ tissue from damage or injury mediated by oxygen-derived free radicals that are generated during the necessary… | Pharmacia-Chiron Partnership | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA